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Objectives. This study sought to investigate whether determi-
nation of tissue viability by means of positron emission tomogra-
phy (PET) before coronary artery bypass graft surgery (CABG)
affects clinical outcome with respect to both in-hospital mortality
and 1-year survival rate.
Background. Patients with coronary artery disease (CAD) and
severe left ventricular (LV) dysfunction are at higher risk for
perioperative complications associated with CABG. Therefore, the
selection of patients who will benefit from CABG is an important
clinical issue.
Methods. This study retrospectively evaluated 76 patients with
advanced CAD and LV dysfunction (LV ejection fraction <20.35)
who were considered candidates for CABG. Thirty-five patients
were selected for CABG on the basis of clinical presentation and
angiographic data (group A), and 34 of 41 patients were selected
according to extent of viable tissue determined by PET (group B)
in addition to clinical presentation and angiographic data.
Results. There were four in-hospital deaths (11.4%) in group A
and none in group B (p 5 0.04). After 12 months, the survival rate
was 79% in group A and 97% in group B (p 5 0.01). Postopera-
tively, group B patients had a less complicated recovery (p 5
0.05). They required lower doses of catecholamines (p 5 0.002)
and demonstrated a significantly decreased incidence of low
output syndrome (p 5 0.05).
Conclusions. This retrospective data analysis suggests that
selection of patients with impaired LV function on the basis of
extent of viability supplementary to clinical and angiographic data
may lead to postoperative recovery with a low early mortality and
promising short-term survival. Therefore, viability studies permit
selection of patients who are at low risk for serious perioperative
complications.
(J Am Coll Cardiol 1997;30:1693–700)
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Previous studies (1–5) have shown that long-term survival after
coronary artery bypass graft surgery (CABG) is better than
that after medical treatment alone in patients with severe left
ventricular (LV) dysfunction. In patients with congestive heart
failure due to ischemic heart disease receiving only medical
treatment, a 2-year survival rate of only 31% has been reported
(6). In contrast, several studies (1–5,7,8) have indicated that
patients with a left ventricular ejection fraction (LVEF) ,30%
benefit most from revascularization. However, perioperative
morbidity and mortality are high in the subgroup of patients
with advanced three-vessel coronary artery disease (CAD),
congestive heart failure and impaired LV function. The in-
hospital mortality rate ranges from 5% to 20%, depending on
LVEF and severity of congestive heart failure (1,9–12). There-
fore, it is important to select patients who are likely to benefit
from the long-term effect of CABG.
Noninvasive imaging, such as positron emission tomogra-
phy (PET), has been reported to be a useful tool for the
determination of tissue viability and hence for the prediction of
reversibility of regional LV dysfunction. PET using nitrogen-13
(N-13) ammonia and fluorine-18 fluorodeoxyglucose (F-18
FDG) has been shown (13,14) to be highly specific in distin-
guishing viable from nonviable or scarred myocardium. After
successful revascularization, improvement of regional wall
motion is expected to occur in 78% to 92% of myocardial
segments viable on PET (15–19). In addition, recent studies
have indicated that myocardial tissue characterization by PET
has prognostic significance. Eitzman et al. (20) showed that the
presence of metabolically compromised myocardium identifies
patients with a significantly higher rate of cardiac complica-
tions in the absence of coronary revascularization. Di Carli et
al. (21,22) reported that the magnitude of decrease in heart
failure symptoms after CABG is related to the preoperative
extent and magnitude of myocardial viability. However, there
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has been no study to date concerning the impact of myocardial
viability assessed by PET on short-term outcome in patients
undergoing surgical revascularization.
Therefore, to examine the influence of selection criteria
based on “viability testing” on short-term outcome after
CABG, patients with significant three-vessel disease and se-
vere LV dysfunction who underwent CABG were retrospec-
tively evaluated. Perioperative morbidity and mortality were
compared in patients selected for revascularization on the
basis of clinical status and angiographic data alone versus
patients who underwent preoperative tissue viability assess-
ment by PET and were selected according to angiographic
data, clinical status and extent of tissue viability.
Methods
Study groups. We retrospectively reviewed 76 consecutive
patients with advanced three-vessel CAD and severe LV
dysfunction (LVEF #0.35) who were referred for CABG or
cardiac transplantation to our institution from January 1994 to
November 1995. All patients gave written informed consent for
this study. Cardiac catheterization was performed in all pa-
tients to assess ventricular function and extent of CAD. Global
LVEF was measured by biplane cineangiography. Advanced
three-vessel disease was defined as a visually estimated lumen
narrowing of at least 75% of the diameter of each of the three
major vessels or their major branches. Patients with LV
aneurysm or concomitant valve disease were excluded from the
study. Most patients in group A had angina pectoris, and the
angiographic results indicated distal coronary vessels suitable
for CABG. In Group B, patients had preoperative tissue
viability assessment by PET in addition to cardiac catheteriza-
tion. PET was requested by the cardiac surgeons for patients in
whom the angiographic report showed coronary arteries that
were considered technically difficult for revascularization and
included arteries in which the estimated target vessel size was
considered too small or in which no collateralization was
angiographically present in cases of proximal coronary artery
occlusion. PET was also performed in patients who were
referred as possible candidates for cardiac transplantation and
in patients who had symptoms of congestive heart failure
primarily, without angina pectoris. PET was also ordered in
eight patients who had previously been rejected for CABG at
other institutions.
PET studies. All patients without known diabetes mellitus
were studied in the postprandial state after additional oral
glucose loading with 50 g of glucose. Patients with known
diabetes or abnormal glucose tolerance received insulin before
and during the imaging sequence, according to a standardized
protocol (23). After initial transmission scanning for attenua-
tion correction, rest regional myocardial perfusion imaging
with N-13 ammonia (740 MBq) was performed. After sufficient
time for N-13 decay, F-18 FDG (370 MBq) was injected, and
data acquisition was initiated 40 min after tracer injection.
Transaxial planes were obtained using whole-body PET (Sie-
mens CTI 951 or Siemens Exact 47). Attenuation-corrected
transaxial PET images were generated from N-13 ammonia
and F-18 FDG data. The images were reoriented perpendicu-
lar to the long axis of the left ventricle, after which volume-
weighted polar maps were calculated from circumferential
profiles of the maximal myocardial activity. In addition, the
transaxial image data were realigned to generate images in
short-axis, vertical and horizontal long-axis views for visual
analysis (20). Regional tracer uptake of N-13 ammonia and
F-18 FDG was evaluated visually, in blinded manner, by two
experienced observers (S.N., M.S.) who had no knowledge of
the clinical and angiographic data, to estimate the extent of
necrosis and viable tissue.
Viability criteria. Tissue viability by PET was assessed by
the combined interpretation of perfusion and metabolism
within the vascular territories of the left ventricle. The septal,
anterior and anterolateral walls were considered the vascular
territory of the left anterior descending coronary artery. The
left circumflex coronary artery was considered to supply the
lateral and posterolateral walls, whereas the vascular territory
of the right coronary artery was the inferior and posterior
walls. Two different viability criteria were used: 1) reduced
blood flow with preserved or increased F-18 FDG uptake
(mismatch); 2) normal or near-normal blood flow with normal
or increased F-18 FDG uptake (normal). Reduced blood flow
with reduced F-18 FDG uptake (matched defect) was used as
the criterion for scar. On the basis of this visual evaluation,
three main criteria were used to determine whether an indi-
vidual patient was a suitable candidate for CABG: 1) The
presence of a “normal or mismatch” pattern in akinetic or
severely hypokinetic myocardial areas supplied by a stenosed
or obstructed artery was required. 2) If viable myocardium was
detected in at least two different vascular territories, we
considered the patient an adequate candidate for CABG,
independent of the estimated target vessel size from the
angiographic report. 3) A large area of scar tissue using an
approximate threshold of 40% was a deciding factor against
CABG. This arbitrary threshold was based on studies of acute
myocardial infarction that indicated a high incidence of car-
diogenic shock in infarct areas .40% of LV mass (38–40). It
was assumed that patients with a large infarct area are more
susceptible to hemodynamic complications during CABG.
The visually estimated extent of scar tissue was retrospec-
Abbreviations and Acryonyms
AICD 5 automatic implantable cardioverter-defibrillator
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
F-18 FDG 5 fluorine-18 fluorodeoxyglucose
ICU 5 intensive care unit
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LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
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tively confirmed by semiquantitative analysis. Scar tissue was
defined as F-18 FDG uptake #50% of maximal uptake on
“bull’s eye” quantitation (24). On the basis of the PET criteria,
in association with the angiographic report, seven patients
were found to be inappropriate candidates for CABG and
either underwent heart transplantation (n 5 4) or received
only medical treatment (n 5 3).
Surgical technique. Complete revascularization was at-
tempted in all patients. For myocardial protection, cold cris-
talloid cardioplegic solution with topical cooling of the heart
and moderate systemic hypothermia (28°C) was used (25).
After cessation of cardiopulmonary bypass, the venous grafts
were measured with electromagnetic flow probes.
Follow-up. Three- to 28-month ([mean 6 SD] group A:
12.0 6 8.5, group B: 14.5 6 5.8) postoperative follow-up
information was obtained for all patients by telephone inter-
view. Heart failure status was classified according to New York
Heart Association criteria. In addition, all patients who under-
went postoperative radionuclide ventriculography (RNV) were
seen by a physician.
RNV. RNV was performed in both groups for functional
follow-up. Red blood cells were labeled with 950 MBq
technetium-99m using an in vivo technique, and images were
obtained with a scintillation camera (Siemens, Basicam SI
plus) equipped with a 140-keV low energy all-purpose colli-
mator. Data acquisition was carried out in three standard
projections. Global LVEF was calculated using commercially
available software (Siemens). A regression equation (RNV
LVEF 5 0.86 3 Biplane angiographic LVEF 1 2.9) was used
to compare preoperative biplane cineangiographic LVEF with
the results of RNV, according to Wackers et al. (26).
Postoperative outcome and definitions. Perioperative and
postoperative complications and mortality were recorded pro-
spectively as part of an ongoing quality assurance program.
In-hospital mortality was defined as death within 30 days of
operation or during hospital stay. Low output syndrome was diag-
nosed when high inotropic medication (dopamine $10 mg/kg
body weight per min) was required to maintain a systolic blood
pressure .80 mm Hg or when intraaortic balloon pumping was
used to sustain adequate hemodynamic status. In patients
whose cardiac output measurements were available, a cardiac
index ,2.5 liters/min per m2 was considered a criterion of low
output syndrome. Cardiopulmonary resuscitation was per-
formed in patients with rhythm disturbances, including ventric-
ular tachycardia compromising hemodynamic condition or
ventricular fibrillation. Uncomplicated recovery was defined as
transfer from the intensive care unit within 2 days.
Statistical analysis. The Student t test for independent
samples for continuous and chi-square analysis for categoric
variables were used to evaluate differences between groups. A
two-tailed p value ,0.05 was considered statistically signifi-
cant. Multivariate logistic regression analysis was performed to
assess the combined impact of several risk factors on outcome
by means of a forced-entry model with SPSS for windows
version 6.0. Kaplan-Meier curves were calculated to estimate
midterm survival; differences between groups were assessed
with the log-rank test.
Results
From January 1994 to November 1995, 69 of 76 referred
patients with advanced three-vessel disease and marked LV
dysfunction underwent CABG at our institution. Thirty-five of
these patients (group A) were selected for revascularization on
the basis of clinical status and angiographic data alone. The
remaining 34 patients (group B) underwent additional tissue
viability assessment by PET.
Comparative demographics. Table 1 depicts the main pre-
operative clinical characteristics of both groups. There were no
significant differences in comparative demographics between
groups A and B. In addition, multivariate logistic regression
analysis showed no difference between the two groups accord-
ing to their preoperative risk profile. Assessment of preoper-
ative risk according to the Higgins et al. (27) clinical severity
score also demonstrated no difference between the two groups.
Operative management. In all cases the same technique
was used for myocardial protection. The mean cross-clamp
time was similar in both groups. The left internal mammary
artery (IMA) was used slightly less often in group A (80% in
group A vs. 85.3% in group B), and an average of 3.7 distal
anastomoses/patient were performed in the two groups. In
group A, one patient required balloon counterpulsation, and
two patients developed a low output syndrome intraopera-
tively. No intraoperative complications occurred in group B.
Table 1. Preoperative Patient Characteristics
Group A
(n 5 35)
Group B
(n 5 34) p Value
LVEF (%) 29.6 6 5.2 27.7 6 4.6 0.12
Range 17–35 18–35
LVEDP (mm/Hg) 18.8 6 9.0 18.9 6 10.5 0.99
LVEDVI (ml/m2) 120.8 6 33.4 135.5 6 36.0 0.16
LVESVI (ml/m2) 85.8 6 25.0 95.8 6 29.9 0.22
NYHA III/IV (%) 68.6 73.5 0.65
History of CHF (%) 40 56 0.19
Previous MI (%) 85.7 67.6 0.08
Age (yr) 60.3 6 10.4 63.2 6 9.2 0.23
.70 yr 8 9 0.95
Female gender (%) 20 8.8 0.19
Reoperation (%) 0 5.9 0.15
DM (%) 34.3 29.4 0.66
Urgency (%) 51 47 0.30
Left main stenosis (%) 22.9 23.5 0.95
Higgins score 5.9 6 2.8 6.1 6 2.8 0.77
Data presented are mean value 6 SD or percent of patients. CHF 5
congestive heart failure; DM 5 diabetes mellitus; Group A 5 patients selected
for revascularization on the basis of clinical status and angiographic data alone;
Group B 5 patients undergoing additional tissue viability assessment by positron
emission tomography; LVEDP 5 left ventricular end-diastolic pressure;
LVEDVI 5 left ventricular end-diastolic volume index; LVESVI 5 left ventric-
ular end-systolic volume index; MI 5 myocardial infarction; Urgency 5 opera-
tion within 14 days of catheterization.
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The electromagnetic bypass flow measurements after extracor-
poreal circulation did not indicate any differences between the
two groups (mean blood flow, group A: 187 6 98 ml/min
[range 48 to 490]); mean blood flow, group B: 185 6 62 ml/min
[range 45 to 380]). Mean blood flow in patients who died was
143 6 72 ml/min; however, there was no statistically significant
difference between patients who died in the early postoperative
period and survivors. Nine different surgeons performed the
operations; no association was found between surgeon and
outcome.
Surgical outcome. Table 2 depicts the perioperative out-
come of both groups. No patient died during operation. On
admission to the intensive care unit (ICU), nearly 30% of
group B patients required no catecholamine support (p 5
0.002) and demonstrated a significantly decreased incidence of
low output syndrome (p 5 0.05), whereas 14% of group A
patients (p 5 0.09) required cardiopulmonary resuscitation
because of rhythm disturbances. Seven of 35 group A patients
and 14 group B patients had an uncomplicated recovery (p 5
0.05). Four patients (11.4%) in group A died in the hospital.
Death occurred postoperatively on days 2, 8 and 15 and at 2
months, respectively. One patient died of arrhythmia-related
causes; one patient had electrocardiographic changes compat-
ible with a postoperative infarction; and two patients died
primarily due to worsening heart failure. In contrast, there
were no in-hospital deaths in group B (p 5 0.04). After 3
months, the mortality rate did not change; however, one group
A patient underwent heart transplantation because of worsen-
ing congestive heart failure after CABG.
Follow-up. The duration of follow-up in the two groups was
913 patient-months. In group A, follow-up ranged from 3 to 28
months (mean 12.0, median 12.3). During this period, five
patients in group A (17.2%) died at 8, 12, 13, 14 and 22
months, respectively, after operation. Twenty-five patients
attained a 6-month, 18 patients a 12-month, 9 patients an
18-month and 5 patients a 24-month follow-up survival time.
The remaining patients had either ,6 months of follow-up
(four patients), or it was not possible to contact them (one
patient). In these patients, the cause of death was cardiac
related in four patients and was due to rhythm disturbances
and worsening of heart failure; in one patient, the cause of
death was cancer. In group B, the follow-up period ranged
from 6 to 25 months (mean 14.5, median 14.6). After 4 months,
one patient (2.9%) died of worsening of heart failure. In group
B, 33 patients attained a 6-month, 22 patients a 12-month, 10
patients an 18-month and 1 patient a 24-month follow-up
survival time. The survival curve (Fig. 1) includes in-hospital
mortality and mortality during follow-up and shows signifi-
cantly different survival between the two groups. After 12
months, the survival rate was 79 6 8% in group A and 97 6 3%
in group B (p , 0.01). Figures 2 and 3 compare the preoper-
ative and postoperative functional and symptomatic data.
Postoperative functional class was recorded for all patients
available for follow-up 3 to 28 months after operation. Most
patients showed marked improvement. The majority of pa-
tients were asymptomatic or minimally symptomatic and were
in functional classes I and II. However, seven patients (28%) in
group A were still in functional classes III and IV. One patient
in this group underwent heart transplantation because of
worsening congestive heart failure 3 months after CABG. In
contrast, only two patients in group B were in functional class
III, and none were in functional class IV (p 5 0.02). Mean
congestive heart failure class improved from 3.1 preoperatively
to 1.8 in group A and from 3.0 to 1.6 in group B.
Follow-up data concerning functional status were evaluated
according to preoperative and postoperative LVEF obtained
Table 2. Perioperative Outcome and Complications
Group A Group B p Value
No catecholamine support 0% 29.4% 0.002
Low output syndrome 17.1% 2.9% 0.05
Cardiac arrest (ICU) 14.3% 2.9% 0.09
Uncomplicated recovery 33.3% 66.7% 0.05
Mortality
30 days 11.4% 0% 0.04
12 mo 14.3% 2.9% 0.02
HTX after CABG 1 Pt 0 Pt
CABG 5 coronary artery bypass graft surgery; HTX 5 heart transplanta-
tion; ICU 5 intensive care unit; Pt 5 patient. Figure 1. Actuarial survival curve (6SE) with the hospital mortality
included. Diamonds 5 group A; circles 5 group B (p , 0.01).
Figure 2. Change in New York Heart Association functional class in
the two groups after revascularization. Mean functional class improved
from 3.1 to 1.8 in group A and from 3.0 to 1.6 in group B. post 5 after
CABG; pre 5 before CABG.
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by radionuclide ventriculography. Because RNV data were not
available preoperatively, a regression equation was used to
normalize contrast angiographic LVEF to equilibrium radio-
nuclide LVEF. This normalization shows only minor differ-
ences between both techniques (group A: angiographic LVEF
31.6 6 4.3% vs. LVEF RNV 29.8 6 3.7%; group B: angio-
graphic LVEF 27.2 6 4.9% vs. LVEF RNV 26.2 6 4.3%).
Forty-four patients (75%) of the 59 survivors underwent this
procedure. Fifteen patients declined the investigation. LVEF
was determined at a mean of 12.4 months in group A and a
mean of 12.5 months in group B after operation. In group A,
mean LVEF increased from 29.8 6 3.7% to 34.3 6 12.4%
(change in LVEF 16.6%), which was not significant. In group
A, LVEF decreased substantially in six patients, with a maxi-
mal decrease of 18 percentage points. The largest improve-
ment was 27 percentage points. In four patients, LVEF
returned to near-normal values. In contrast, LVEF in group B
patients showed a significant increase; mean LVEF improved
from 26.2 6 4.3% to 34.8 6 12.2% (change in LVEF 36.2%,
p 5 0.003). Only three patients showed a decrease in LV
function. The maximal decrease was 18 percentage points, and
the largest improvement was 31 percentage points. Of group B
patients, six attained nearly normal ventricular function. How-
ever, the follow-up LVEF values were not significantly differ-
ent between the two groups (34.3% [group A] vs. 34.8% [group
B]).
Discussion
The results of the present study suggest that selection of
patients on the basis of tissue viability assessed by PET
supplementary to clinical and angiographic data leads to a
postoperative recovery with a low early mortality and promis-
ing short-term survival after CABG. In contrast, in patients
who were selected for revascularization on the basis of clinical
status and angiographic data alone, the outcome confirms
previously published high complication and mortality rates.
To our knowledge, this study is the first to examine the
effect of preoperative assessment of tissue viability on periop-
erative and postoperative complications in patients with ad-
vanced three vessel CAD and severe LV dysfunction. This
subgroup of patients shows the greatest long-term benefit from
surgical revascularization (3,4) and has been confirmed by
Elefteriades et al. (10) who showed excellent survival in a
comparable group of patients up to 3 years after CABG.
However, the in-hospital mortality in that study was reported
to be 8.4% in the patient group selected for revascularization
without preoperative viability assessment. Similarly, in-hospital
mortality in the present study was ;11% in patients without
preoperative PET, whereas patients with preoperative PET
imaging had very low in-hospital mortality. Thus, these data
suggest that PET may provide unique information, indepen-
dent of other established prognostic markers, for identifying
patients who are at low risk for early complications associated
with coronary revascularization. The identification of viable
myocardium using imaging approaches such as PET appears to
be clinically relevant in patients with advanced CAD and
severely impaired LV function who are being considered for
revascularization.
Risk assessment. Several studies concerning risk factors
for morbidity and mortality in patients undergoing CABG have
been reported. Christakis et al. (9) found that emergency
revascularization, LV dysfunction, age and previous bypass
operation remain significant predictors of operative mortality;
however, improved techniques for heart surgery in recent years
have neutralized many traditionally accepted risk factors, such
as gender, left main coronary artery stenosis and number of
diseased vessels (28,29). In our investigation, all patients in
groups A and B had significant three-vessel disease and
severely impaired LV dysfunction as assessed by contrast
ventriculography, with no difference in preoperative LVEF
between the two groups. All other preoperative clinical and
demographic data were not significantly different and are
therefore comparable in both groups (Table 1). In addition,
multivariate logistic regression analysis taking into account the
impact of several risk factors simultaneously showed no differ-
ences between the two groups. The operative risk of each
patient was ranked using the clinical severity score determined
by Higgins et al. (27), which is a widely accepted system for
preoperative estimates of morbidity and mortality risks. This
Figure 3. Change in global LV function
expressed as LVEF. There is a modest
increase from 29.8% to 34.3% in group A
and from 26.2% to 34.8% in group B.
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score also failed to show differences between the two groups.
Therefore, differences in patient characteristics, insofar as
known risk factors are concerned, can be excluded in account-
ing for the observed differences in mortality.
Operative methods and treatment in the ICU. All patients
underwent surgical revascularization using the same surgical
and myocardial protective techniques. The IMA was used in
the majority of patients; 80% of group A patients and 85.3% of
group B patients received the left IMA as a conduit to the left
anterior descending coronary artery. It is unlikely that any
differences in postoperative treatment of patients in either
group is responsible for the observed differences in complica-
tion and mortality rates. The physicians in the ICU were not
aware of whether a patient had undergone PET imaging;
therefore, treatment bias can be excluded as a source of the
observed differences in outcome. Observation bias is equally
unlikely because data concerning patient characteristics and
perioperative events were collected prospectively as part of our
ongoing quality assurance program.
On admission to the ICU, approximately one-third of group
B patients required no catecholamine support, which suggests
improved LV function after CABG. Topol et al. (30) showed
that immediate improvement in regional wall thickening after
CABG was most marked in those segments with the most
severe preoperative dysfunction. The functional outcome of
regional myocardial segments after CABG was not investi-
gated in the present study. However, more rapid functional
improvement in viable myocardial segments may be an expla-
nation for the lower need for catecholamine support. Of the
patients who were transferred from the ICU within 2 days with
uncomplicated recovery, nearly 70% were from group B. All
patients (except one) who were treated initially without any
catecholamines were discharged within 2 days from the ICU.
One may again speculate that the more rapid improvement in
regional ventricular function was responsible for faster clinical
recovery after operation.
Seventeen percent of group A patients developed low
output syndrome, and 14% required cardiopulmonary resusci-
tation because of malignant arrhythmias. Blakeman et al. (31)
showed that the occurrence of malignant arrhythmias is a
significant risk factor in patients with severe LV dysfunction
undergoing CABG. The use of an automatic implantable
cardioverter-defibrillator (AICD) may avoid sudden death
after hospital discharge and should improve the intermediate
and long-term survival. In the present study, two patients from
both groups received an AICD after CABG; therefore, more
frequent use of AICDs is not likely to be a reason for the
different results among the two groups. In the perioperative
period, patients in group A showed a tendency (p 5 0.09) to be
more susceptible to the development of malignant arrhyth-
mias, which may be due to their somewhat higher (p 5 0.08)
rate of previous myocardial infarction. Another explanation
may be that group A patients had a greater extent of scar
tissue, which may have predisposed them to postoperative
arrhythmias. However, this explanation remains speculative
because we did not perform assessment of infarct size in group
A to assess the extent of scar tissue in these patients.
As the retrospective semiquantitative analysis of PET data
have demonstrated, most patients with preoperative tissue
viability assessment had areas of scar tissue comprising ,20%
of the left ventricle. The small infarct size may explain the
significant reduction in incidence of low output syndrome and
early mortality rate. The functional capacity of the remaining
myocardium was probably sufficient to prevent the develop-
ment of low output syndrome or early mortality due to
myocardial failure.
Viability assessment. Viable myocardium in dysfunctional
segments was defined as a region with normal blood flow or
with reduced blood flow but with preserved or increased F-18
FDG uptake. This definition includes increased glucose uptake
in segments with reduced blood flow (flow–metabolism mis-
match), which may represent the metabolic expression of
hibernating myocardium (13,14). In addition, recent studies
have indicated that in patients with myocardial hibernation,
the loss of regional contraction is out of proportion to the
reduction in myocardial blood flow (perfusion–contraction
mismatch). Chronic reversible dysfunction in hibernating myo-
cardium is not only caused by chronic hypoperfusion, but may
be the consequence of repeated episodes of ischemia followed
by myocardial stunning (32). Normal or increased glucose
uptake in regions with normal or near-normal blood flow at
rest may also represent the metabolic expression of stunned
myocardium, which is characterized by a flow–function mis-
match (33). Preliminary results suggest that scintigraphic pat-
terns of “stunning” are more pronounced than that of “hiber-
nation” in patients with marked LV dysfunction (34). The
present study did not distinguish between both pathophysio-
logic representations of dysfunctioning myocardium. Stunned
and hibernating myocardium may be associated with severe
impairment of contractile function and worsening of heart
failure; however, both conditions have shown functional recov-
ery after revascularization (35,36).
Two main viability criteria were used in the selection of
patients who were referred for CABG: 1) the presence of
viable myocardium in akinetic myocardial areas that were
supplied by a stenosed or obstructed artery. 2) If viable
myocardium was detected in at least two different vascular
territories, then that patient was considered an adequate
candidate for CABG. Extent of scar tissue .40% of the left
ventricle was a deciding factor against CABG because post-
mortem studies (37–39) have shown that patients who died of
cardiogenic shock after acute myocardial infarction had large
infarct areas, averaging 37%, 43% and 51% of LV mass, which
may indicate an irreversible and untractable condition. Yo-
shida and Gould (40) showed that the size of the infarct area
and viability in arterial zones at risk assessed by PET are good
prognostic indicators of mortality, particularly in patients with
LV dysfunction. In their study, 6 of 35 patients had an infarct
size between 39% and 77%, as determined by quantitative
PET measurements. Four of these patients had died within a
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3-year follow-up period, three of them after percutaneous
transluminal coronary angioplasty or CABG.
Nevertheless, the criterion of scar extent .40%, which was
applied in the present study, represents an arbitrary threshold.
As the retrospective semiquantitative analysis in the present
study showed, the criterion of scar extent alone is not sufficient
for the selection process in some patients. One group B patient
had a scar tissue area of 43%. However, in this patient the
other main viability criteria and the angiographic report sup-
ported the decision that this patient was an adequate candidate
for CABG. Therefore, in patients with a scar tissue area
;40%, the criterion of scar tissue area should only be applied
in combination with the other viability criteria as well as
angiographic results.
Most patients who underwent revascularization had a scar
tissue area comprising ,20% of the left ventricle, which
confirms previous observations that advanced symptoms of
heart failure do not exclude the presence of extensive areas of
viable myocardium. In addition, all patients who were previ-
ously rejected for CABG on the basis of clinical status and
angiographic data from other institutions showed a scar tissue
area by PET data of ,20%, indicating that selection of
patients for operation without viability assessment may be
insufficient. PET may therefore provide a better selection
process that extends the indication for operation to patients
who are likely to benefit from revascularization but would have
otherwise been rejected.
Study limitations. In interpreting the results of the present
study, several limitations should be recognized:
1. The main limitation is that the present study did not
involve randomization of patients. The study included patients
with severe reduction of LV function who were referred for
revascularization. Limited availability of PET and outside
referral prohibited prospective randomization of patients in
this study. Although a randomization protocol would have
been ideal, careful retrospective analysis of risk factors was
performed in both groups to identify any selection bias. The
incidence of heart failure was slightly higher in the PET group
than in the control group, suggesting possibly sicker patients in
the PET group. Overall, there was no significant difference
detected in preoperative risk factors between the two groups.
However, we cannot exclude the possibility that other variables
may have contributed to the improved survival in group B.
After multivariate statistical adjustment for important clinical
differences between the two groups, we observed a significant
advantage in early mortality for group B. The unadjusted odds
ratio for early mortality (group B vs. group A) was 0.09
compared with the adjusted odds ratio of 0.06 after controlling
for age, gender, preoperative functional class, history of con-
gestive heart failure, previous myocardial infarction, LVEF,
left main coronary artery stenosis, priority of operation, dia-
betes mellitus and reoperation. This finding suggests that the
observed improved outcome in group B is not attributed to
differentially distributed risk factors. Therefore, the statement
that PET provides unique information for appropriate selec-
tion of patients with LV dysfunction appears to be valid.
2. Symptomatic status was assessed using New York Heart
Association functional class, a widely used system for estimat-
ing quality of life. In the present study we did not use the
Canadian Cardiovascular Society classification (41) because
the predominant symptom in the majority of patients was
dyspnea on exertion rather than angina pectoris. In both
groups, we found improvement in congestive heart failure
status after operation; however, in group A significantly more
patients remained in functional class III or IV postoperatively.
Moreover, in some patients the evaluation of the symptomatic
status according to functional class is limited because it
remains unclear how much improvement in functional class
resulted from decreased angina rather than improvement in
dyspnea on exertion. To determine actual improvement in
LVEF, postoperative RNV was performed at varying intervals
at rest. Consequently, we did not control for physiologic factors
that may influence LVEF. However, all patients who under-
went RNV did so at least 3 months after operation, at which
time surgically induced depression of LV function, residual
myocardial stunning or catecholamine-induced functional im-
provement should no longer be present. Mean rest LVEF rose
from 29.8% to 34.3% in group A and from 26.2% to 34.8% in
group B, indicating a trend toward improved global LV
function after CABG in both groups. However, it should be
emphasized that preoperative LVEF was determined by con-
trast angiography, and postoperative LVEF was determined in
all patients by equilibrium RNV. Therefore, a direct compar-
ison between preoperative and postoperative LVEF is limited.
For this reason, a regression equation (26) was used to
normalize preoperative contrast angiographic LVEF to the
equilibrium radionuclide LVEF. The calculation showed a
modest enhancement of LV function in both groups. This
functional improvement may be responsible for the ameliora-
tion of congestive heart failure symptoms.
3. This study did not include a comparison of PET with
other imaging modalities for detection of viable myocardium.
Further studies are necessary to determine whether the same
results may be obtained with conventional scintigraphic tech-
niques, such as thallium-201 imaging or low dose dobutamine
echocardiography.
Conclusions. Selection of patients on the basis of tissue
viability assessment using PET in combination with F-18 FDG
and N-13 ammonia, in addition to clinical status and angio-
graphic data, led to postoperative recovery with fewer compli-
cations and a significant decrease in early mortality in patients
with severe LV dysfunction undergoing CABG compared with
patients selected on the basis of clinical and angiographic
results alone. Our results suggest that preoperative assessment
of myocardial viability should be considered to identify pa-
tients at lower risk of perioperative complications and mortal-
ity associated with revascularization. Furthermore, this selec-
tion process may extend the indication for operation to
patients otherwise excluded. Therefore, viability studies may
not only provide prognostic information with regard to recov-
ery of function after revascularization, but also permit selec-
tion of patients who are at low risk for serious perioperative
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complications. Additional studies, preferably randomized trials
with a large patient population, are required to confirm the
results of the present study.
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for editorial assistance in the preparation of the manuscript.
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